JAZZ
Jazz Pharmaceuticals plc
NASDAQ · Healthcare · Biotechnology · IE
$246.81
−0.30%0
Insider buys (3m)
11
Insider sells (3m)
-$24.2M
Net value (3m)
+3.6%
Price return (3m)
Form 4 filings
| Date | Insider | Activity | Shares | Price |
|---|---|---|---|---|
| Sep 2, 2026 | RIEDEL NORBERT G · director | F-InKind | 1,692 | $241 |
| Sep 2, 2026 | Kennedy Patrick · director | F-InKind | 15 | $244 |
| Sep 2, 2026 | ENRIGHT PATRICK G · director | F-InKind | 1,692 | $241 |
| Sep 2, 2026 | Smith Mark Douglas · director | F-InKind | 1,692 | $241 |
| Sep 2, 2026 | Hamill Laura · director | F-InKind | 14 | $244 |
| Sep 2, 2026 | ENRIGHT PATRICK G · director | F-InKind | 14 | $245 |
| Sep 2, 2026 | Henderson Mary Elizabeth · officer: SVP, Technical Operations | F-InKind | 2,076 | $241 |
| Sep 2, 2026 | Winningham Rick E · director | F-InKind | 14 | $245 |
| Sep 2, 2026 | COZADD BRUCE C · director | F-InKind | 1,209 | $241 |
| Sep 2, 2026 | McSharry Heather Ann · director | F-InKind | 1,840 | $241 |
| Sep 2, 2026 | Cook Jennifer E. · director | F-InKind | 14 | $244 |
| Sep 2, 2026 | McSharry Heather Ann · director | F-InKind | 15 | $245 |
| Sep 2, 2026 | Cook Jennifer E. · director | F-InKind | 1,692 | $241 |
| Sep 2, 2026 | Henderson Mary Elizabeth · officer: SVP, Technical Operations | F-InKind | 16 | $245 |
| Sep 2, 2026 | LOVE TED W · director | F-InKind | 6 | $244 |
| Sep 2, 2026 | RIEDEL NORBERT G · director | F-InKind | 14 | $245 |
| Sep 2, 2026 | COZADD BRUCE C · director | Sale | 6,000 | $250 |
| Sep 2, 2026 | LOVE TED W · director | F-InKind | 737 | $241 |
| Sep 2, 2026 | Kennedy Patrick · director | F-InKind | 1,840 | $241 |
| Sep 2, 2026 | Winningham Rick E · director | F-InKind | 1,692 | $241 |
| Sep 2, 2026 | COZADD BRUCE C · director | F-InKind | 10 | $244 |
| Sep 2, 2026 | Smith Mark Douglas · director | F-InKind | 14 | $245 |
| Sep 2, 2026 | Hamill Laura · director | F-InKind | 1,692 | $241 |
| Aug 31, 2026 | Iannone Robert · officer: EVP, Global Head of R&D & CMO | M-Exempt | 884 | $113 |
| Aug 31, 2026 | Iannone Robert · officer: EVP, Global Head of R&D & CMO | M-Exempt | 26,116 | $113 |
| Aug 31, 2026 | Iannone Robert · officer: EVP, Global Head of R&D & CMO | M-Exempt | 2,916 | $137 |
| Aug 31, 2026 | Iannone Robert · officer: EVP, Global Head of R&D & CMO | Sale | 18,113 | $250 |
| Aug 31, 2026 | Iannone Robert · officer: EVP, Global Head of R&D & CMO | M-Exempt | 27,584 | $137 |
| Aug 31, 2026 | Iannone Robert · officer: EVP, Global Head of R&D & CMO | Sale | 19,639 | $251 |
| Aug 31, 2026 | Iannone Robert · officer: EVP, Global Head of R&D & CMO | Sale | 11,423 | $249 |
Institutional positioning
13F filings over the trailing two quarters
New 228Increased 467Reduced 362Sold out 57
| Filer | Action | Shares | Filed |
|---|---|---|---|
| BlackRock, Inc. | Increased | 5,968,603 | Aug 7, 2026 |
| BLACKROCK, INC. | Increased | 5,591,700 | May 13, 2026 |
| FMR LLC | Increased | 4,609,326 | Aug 13, 2026 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | Increased | 3,036,213 | Aug 13, 2026 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | New Position | 2,983,242 | May 8, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | Increased | 2,729,650 | Aug 13, 2026 |
| Capital World Investors | Increased | 2,697,610 | Aug 12, 2026 |
| CAPITAL WORLD INVESTORS | Increased | 2,673,376 | May 13, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | New Position | 2,648,333 | May 15, 2026 |
| LSV ASSET MANAGEMENT | Reduced | 2,386,840 | May 11, 2026 |
| FMR LLC | Increased | 2,275,762 | May 15, 2026 |
| LSV ASSET MANAGEMENT | Reduced | 2,275,145 | Aug 6, 2026 |
| FRANKLIN RESOURCES INC | Increased | 2,040,250 | Aug 13, 2026 |
| STATE STREET CORP | Increased | 1,999,816 | Aug 7, 2026 |
| FRANKLIN RESOURCES INC | Increased | 1,958,940 | May 13, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing Sep 2, 2026